Beta Bionics reported net sales of $35.5 million for the three months ended September 30, 2026, compared to $27.3 million a year earlier. The net loss for that period was $24,353 thousand, versus $14,209 thousand. Mint patch pump received FDA clearance on September 14, 2026, with full U.S. commercial launch expected in the first quarter of 2027.
BBNX · Beta Bionics, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 55%
- Last earnings
- Oct 27, 2026
- Latest filing
- 10-Q · Oct 27
- Price history
- Jan 2025 to Nov 2026
Up next
Latest documents
Beta Bionics reported third-quarter 2026 net sales of $35.5 million, up 30% from $27.3 million a year earlier, with a net loss of $24.4 million. The company raised its low-end full-year 2026 revenue guidance to $124 million to $126 million from $121 million to $126 million, noting a potential deferral of up to $8.5 million in the fourth quarter as prospective users may await Mint. It also withdrew its 3D Intelligence 510(k) application and plans to resubmit it in mid-Q4 2026.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -17.66M | the three months ended June 30, 2026 filing | — |
|
|
|||
| Durable Medical Equipment (DME) channel net sales | $20.4M | second quarter of 2026 | — |
| Net sales generated through the DME channel | 64% | the three months ended June 30, 2026 filing | — |
| Net sales generated through the PBP channel | 36% | the three months ended June 30, 2026 filing | — |
| Pharmacy Benefit Plan (PBP) channel net sales | $11.6M | second quarter of 2026 | — |
| single-use products accounted for net sales | 60% | the three months ended June 30, 2026 filing | — |
| Total DME channel | 20.41M | the three months ended June 30, 2026 filing | — |
| Total PBP channel | 11.6M | the three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BBNX
this stock
Beta Bionics, Inc.
|
$726.34M | -56.2% | +53.9% | — | 9.2% |
|
ABT
Abbott Laboratories
|
$178.39B | -17.8% | +5.7% | 38.4 | 1.1% |
|
MDT
Medtronic plc
|
$127.84B | +4.0% | +8.4% | 24.6 | 1.8% |
|
SYK
Stryker Corp
|
$118.01B | -11.8% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$60.85B | -56.0% | +12.5% | 17.8 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 27, 2026
- This year
- 18
Beta Bionics reported third-quarter 2026 net sales of $35.5 million, up 30% from $27.3 million a year earlier, with a net loss of $24.4 million. The company raised its low-end full-year 2026 revenue guidance to $124 million to $126 million from $121 million to $126 million, noting a potential deferral of up to $8.5 million in the fourth quarter as prospective users may await Mint. It also withdrew its 3D Intelligence 510(k) application and plans to resubmit it in mid-Q4 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BBNX | -18.6% | -30.3% | +4.5% | -20.2% | -56.2% |
| SPY | -8.6% | -9.2% | -9.2% | -8.7% | +1.2% |
| vs SPY | -10.1% | -21.0% | +13.6% | -11.5% | -57.3% |